The Zantac mass tort began in 2019–2020 following FDA findings that ranitidine (the active ingredient in Zantac) can produce NDMA — a probable human carcinogen — through molecular instability over time. The FDA requested manufacturers withdraw ranitidine products from the U.S. market in April 2020.
The federal MDL was consolidated in the Southern District of Florida (MDL 2924) and was substantially dismissed in late 2022 on Daubert grounds, but state-court litigation continues at substantial volume — particularly in California, Delaware, and Pennsylvania. Multiple defendant manufacturers have entered settlement frameworks at varying stages.
Qualification centers on long-term Zantac or generic ranitidine use combined with qualifying cancer diagnosis (bladder, esophageal, gastric, liver, pancreatic, prostate, others). Per-defendant qualification details vary.
Highfloor supports per-firm Zantac flights with bar TV reaching long-term-user demographics plus broadcast TV reaching the family-decision-maker audience.
- Year-round flights
- Bar TV reaching long-term-user demographic (45-75)
- Broadcast TV during daytime windows
- Search-keyword spend on Zantac-cancer-specific terms
- September 2019 — FDA announces ranitidine NDMA findings
- April 2020 — FDA requests ranitidine market withdrawal
- 2020 — federal MDL formed
- December 2022 — federal MDL substantially dismissed on Daubert grounds
- 2023–2025 — state-court litigation and per-defendant settlement frameworks
- Distributed broadly — long-term ranitidine use was widespread
- Concentration in California, Delaware, Pennsylvania given continued state-court litigation